ReviewCureus2017
Gastrointestinal Amyloidosis: Review of the Literature.
Review in Cureus, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 90 citations in OpenAlex.
- Guideline
- Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.Journal of neurology · 2020Trial
- Isolated jejunal amyloidosis presenting as acute mechanical small bowel obstruction: a rare diagnostic challenge - a case report.International journal of surgery case reports · 2026Article
- Case Report: A rare presentation of gastrointestinal amyloidosis: unmasking the hidden culprit of chronic epigastric pain and weight loss.Frontiers in gastroenterology (Lausanne, Switzerland) · 2026Article
- Bowel Blockage Without a Block: Amyloidosis Presenting as Chronic Intestinal Pseudo-Obstruction.Cureus · 2025Article
- Endoscopic and pathological characteristics of gastrointestinal amyloidosis: a retrospective analysis.BMC gastroenterology · 2025Article
- Systemic Amyloid A Protein Amyloidosis With Gastrointestinal Involvement.ACG case reports journal · 2024Article
- Isolated AL Amyloidosis of the Colon: A Rare Presentation.ACG case reports journal · 2024Article
- A rare cause of colonic pseudo-obstruction due to light chain amyloidosis.Journal of surgical case reports · 2023Article
- Gastrointestinal Bleeding Caused by Large Intestine Amyloidosis.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2023Article
- Teduglutide in amyloidosis-associated intestinal failure.Clinical case reports · 2023Article
- Gastrointestinal AA Amyloidosis following Recurrent SARS-CoV-2 Infection: A Case Report.Yonsei medical journal · 2023Article
- Gastrointestinal (GI) Amyloidosis Presenting As Chronic Diarrhea: A Diagnostic Dilemma.Cureus · 2023Article
- Gastroparesis: an under-recognised manifestation of systemic amyloidosis.BMJ case reports · 2023Article
- Amyloidosis: a case series and review of the literature.Journal of medical case reports · 2023Review
- A Rare Case of Gastrointestinal Amyloidosis Due to Monoclonal Gammopathy of Undetermined Significance.Cureus · 2023Article
- Localized Rectal Amyloidosis with Morphologic Changes from the Submucosal Tumor to the Ulcerative Lesion That Led to Hematochezia During Observation.Internal medicine (Tokyo, Japan) · 2023Article
- Peritoneal Amyloid as a Presenting Manifestation of AL Amyloid.Journal of community hospital internal medicine perspectives · 2023Article
- Amyloidosis and Carpal Tunnel Syndrome: Surgical Technique for Extended Carpal Tunnel Release with Tenosynovium and Transverse Carpal Ligament Biopsies.Plastic and reconstructive surgery. Global open · 2023Article
- Emerging from the shadows: A rare case of gastrointestinal AL amyloidosis presenting as hematemesis.Proceedings (Baylor University. Medical Center) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastrointestinal amyloidosis (GIA), a protein deposition disorder, represents a complex common pathway that encompasses multiple etiologies and presentations. It represents a significant diagnostic and treatment challenge. The disease results from the deposition of insoluble extracellular protein fragments that have been rendered resistant to digestion. GIA can be acquired or genetic, and most commonly results from chronic inflammatory disorders (AA amyloidosis), hematologic malignancy (AL amyloidosis), and end-stage renal disease (Beta-2 amyloidosis). The deposition of these abnormal proteins interferes with gastrointestinal tract (GI) organ structure and function, most notably in the liver and small bowel. Presentation from GI involvement includes cirrhotic sequelae, abdominal pain, malabsorption, and GI bleeding. Diagnosis hinges on pathologic examination of affected tissue, with classic green birefringence under polarized light. Abdominal fat pad and rectal mucosal biopsy have been described as sites of higher sensitivity for diagnosis. Serum amyloid P scintigraphy is near 90% sensitive for diagnosis of AA amyloidosis. Patients should be considered for further evaluation to rule out additional organ involvement, notably cardiac and renal. Treatment hinges on an adequate suppression of the predisposing inflammatory disorder, or malignancy, followed by supportive therapy. Prognosis varies depending on the etiology of the disease, with the AL subtype showing worse outcomes, as well as those with hepatic involvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.